Trial Condition(s):

Cystitis / Pyelonephritis / Cystic fibrosis / Anthrax

Special Drug Use Investigation of Ciproxan injection in pediatrics

Bayer Identifier:

18235

ClinicalTrials.gov Identifier:

NCT02555059

EudraCT Number:

Not Available

Study Completed

Trial Purpose

The objective in this study is collecting post-marketing information on the safety and efficacy of Ciproxan injection under the routine clinical practice.

Inclusion Criteria
- Female and male pediatric patients (less than 15 years old) with a diagnosis of complicated cystitis, pyelonephritis, cystic fibrosis, or anthrax infected by ciprofloxacin-active microorganisms, i.e. Bacillus anthracis, Escherichia coli, Pseudomonas aeruginosa.
 - Patients for whom the decision to initiate treatment with Ciproxan injection was made as per investigator’s routine treatment practice.
Exclusion Criteria
- N/A

Trial Summary

Enrollment Goal
48
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Cipro IV (Ciprofloxacin, BAYQ3939)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, Japan

Status
Completed
 

Trial Design